

Date: 27th May 2023

To,
Listing Compliance Department,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra East, Mumbai-400051

NSE Symbol: Madhavbaug

Sub: Outcome of Board Meeting under Regulations 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")


Pursuant to Regulations 30 of the SEBI Listing Regulations, Board of Directors in its meeting held on Saturday, May 27, 2023 ("Meeting"), inter alia, considered and approved following business:

- Audited Annual Financial Results of the Company, for half year and year ended March 31, 2023. (Annexure-1)
- Recommended final dividend of ₹0.25 per Share of ₹10 each (2.5% per share) for the financial year ended March 31, 2023. The dividend, if declared at the AGM. {date of AGM will be communicated separately}
- Allotment of 5,00,000 share warrants to Dr. Rohit Sane and M/s Medemy Life Sciences Private Limited equally, on preferential basis.
- Appointment of M/s Khare Deshmukh & Co, Chartered Accountants, Pune, as Internal Auditor for F.Y 2023-24 (Annexure-2)
- Appointment of M/s Deep Shukla & Associates, Practising Company Secretaries, Mumbai, as Secretarial Auditor for F.Y 2023-24 (Annexure-3)
- Approval of Statement of Deviation(s) and Variation(s) for period year ended 31st March 2023

The Board Meeting was commenced on 12.30 pm and concluded on 01.55 pm

We would request you to take the above intimation on records.

For, Vaidya Sane Ayurved Laboratories Limited


Abhishek Deshpande
Company Secretary & Compliance Officer



VAIDYA SANE AYURVED LABORATORIES LIMITED

Registered Office Address:

Fl.5.1047, Shriram Bhawan, Shukrawar Peth,
Pune- 411002, Maharashtra India.
CIN No : L73100PN1999PLC013509

Corporate Office Address:

Ishan Bldg. No. 2, 7th Floor, Gokhale Road, Naupada,
Thane (W)-400 602 Tel: +91 022-41235315/16
www.madhavbaug.org



A. A. MOHARE & CO.
CHARTERED ACCOUNTANTS

1/3, Shree Vivekanand CHS Ltd.,
Guru Mandir Road, Saraswat Colony,
Dombivli (East) 421 201.
M : 9223 543 842 / LL : 0251 – 2473000
Email : amit@aamco.in

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF STANDALONE FINANCIAL RESULTS TO THE
BOARD OF DIRECTORS OF VAIDYA SANE AYURVED LABROTORIES LIMITED**

To,
The Board of Directors
Vaidya Sane Ayurved Laboratories Limited
(erstwhile known as Vaidya Sane Ayurved Laboratories Private Limited)
Fl. 5 1047, Shriram Bhawan,, Shukrawar Peth,
Pune, Maharashtra, India, 411002.

Dear Sir,

1. We have reviewed the accompanying Statement of Standalone Audited Financial Results of **VAIDYA SANE AYURVED LABROTORIES LIMITED** (the "Company"), for the year ended March 31, 2023 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Standalone Statement, prepared in accordance with, does not give a true and fair view of the state of affairs of the Group as at March 31, 2023, and of its results of operations and its Standalone cash flows for the year ended in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed.

For A A Mohare & Co.
Chartered Accountants (FRN : 114152W)

CA Amit A Mohare
Partner

Membership No. : 148601

Place : Thane

Date : 27/05/2023

UDIN : 23148601BGWJJP6375



UDIN - 23148601BGWJJP6375

Vaidya Sane Ayurved Laboratories Ltd

Fl No. 5, 1047, Shriram Bhavan, Shukrawar Peth, Pune, Maharashtra 411 002

CIN NO. : L73100PN1999PLC013509

Satndalone Statement of profit and loss for the Half year ended 31st March 2023 and year ended March 31,2023

Amounts in Lakhs

Particulars	For the Half year ended March 31,2023	For the Half Year Ended March 31, 2022	For the Year Ended March 31,2023	For the year ended March 31, 2022
Revenue				
Revenue from operations	5,349.81	4,314.64	9,902.54	7,471.05
Other income	53.58	33.78	136.09	33.88
Total revenue	5,403.40	4,348.42	10,038.63	7,504.93
Expenses				
Cost of materials consumed	1,455.82	1,233.30	2,762.28	2,206.58
Employee benefit expenses	1,109.37	923.71	2,181.00	1,818.67
Finance costs	7.45	9.30	18.75	20.18
Depreciation and amortisation expense	144.26	111.12	259.79	228.57
Other expenses	2,395.78	1,728.82	4,125.77	2,756.04
Total expenses	5,112.69	4,006.25	9,347.59	7,030.04
Profit / (loss) before prior period adjustments & tax.	290.71	342.17	691.04	474.89
Prior period adjustments	-	-	-	-
Profit / (loss) before extraordinary items and tax	290.71	342.17	691.04	474.89
Extraordinary items	-	-	-	-
Profit / (loss) before tax	290.71	342.17	691.04	474.89
Tax expense				
Current tax	72.96	101.89	172.26	119.14
Deferred tax (expense)/income	(0.14)	28.86	(0.22)	8.85
	-	-	-	-
Profit for the year	217.89	211.43	519.00	346.90
Earnings per equity share				
[Nominal value per share Rs. 10 (F.Y. 2021-22 - Rs.10)]				
Basic	2.07	2.01	4.94	8.00
Diluted	2.07	2.01	4.94	8.00

Notes :

- The Audited Financial statement were reviewed by the audit committee and taken on record by the Board of directors at their meeting held on 27th May, 2023
- As required under Regulation 33 of the SEBI (LODR) Regulations, 2015, the Statutory Auditors have issued Audit Reports on the aforesaid audited financial results for the half year & year ended 31st March, 2023, which were also approved by the Audit Committee and board at their meeting held on Saturday, 27th May, 2023.
- The Earning Per Share (EPS) has been computed in accordance with the Accounting Standard on Earnings Per Share (AS 20).
- As per MCA Notification Wltd 16th February, 2015, companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the compulsory requirement of adoption of IND-AS. As the company is covered under the exempted category, it has not adopted IND-AS for preparation of financial results.
- The company has issued and allotted 27,71,200 equity share of face value INR 10/- each at a price of INR 73/- per share through an Initial Public Offer aggregating to INR 2022.98 lakhs. The net issue proceed after excluding Expenses is 1972.98 lakhs. The details of utilization of net IPO Proceeds is mentioned below,

Particulars	As per Prospectus	Actual Utilisation	Pending for Utilisation
Branding & Advertising	1,600.00	1,452.78	147.22
General Corporate Purpose	372.98	372.98	0.00
Total	1,972.98	1,825.76	147.22

For A A Mohare and Co.

Chartered Accountants (FRN 114152W)




Amit Mohare
Partner
Membership No. 148601
Place : Thane

Date : 27/05/2023

UDIN : 23148601BGWJJP6375

For and on behalf of the Board of Directors of**Vaidya Sane Ayurved Laboratories Ltd**


Rohit Sane
MD & CEO
DIN: 00679851

Date : 27/05/2023

Place : Thane



Vidyut Ghag
Whole Time Director
DIN: 09299252

Date : 27/05/2023

Place : Thane



Abhishek Deshpande
Company Secretary

Date : 27/05/2023

Place : Thane



Darshan Shah
CFO

Date : 27/05/2023

Place : Thane



Vaidya Sane Ayurved Laboratories Ltd

Fl No. 5, 1047, Shriram Bhavan, Shukrawar Peth, Pune, Maharashtra 411 002

CIN NO. : L73100PN1999PLC013509

Standalone Balance Sheet as at March 31, 2023

		Amounts in Lakhs	
Particulars		As at	As at
		March 31, 2023	March 31, 2022
I EQUITY AND LIABILITIES			
1. Shareholders' Funds			
Share Capital		1,051.35	1,051.35
Reserves and Surplus		3,029.63	2,536.91
		4,080.98	3,588.26
2. Non-Current Liabilities			
Long-Term Borrowings		-	-
Deferred Tax Liabilities (Net)		4.52	4.75
Long-Term Provisions		155.32	156.55
		159.84	161.30
3. Current Liabilities			
Short-Term Borrowings		13.40	106.33
Trade Payables			
(a) Total outstanding dues of micro enterprises and small enterprises		159.65	145.08
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises		736.29	592.78
Other Current Liabilities		329.59	297.32
Short-Term Provisions		48.13	109.52
		1,287.06	1,251.03
TOTAL		5,527.88	5,000.59
II ASSETS			
1. Non-Current Assets			
Property, Plant & Equipment			
Tangible assets		1,843.43	1,596.40
Intangible assets		251.34	104.38
Capital work in progress		167.21	123.08
Non-Current Investments		105.36	488.13
Long-Term Loans and Advances		278.24	140.80
		2,645.58	2,452.79
2. Current Assets			
Current Investment		1,379.51	1,660.73
Inventory		341.38	150.06
Trade receivables		646.40	355.86
Cash and Bank Balances		175.15	256.09
Short-Term loans and advances		339.86	125.06
		2,882.30	2,547.80
TOTAL		5,527.88	5,000.59

As per our report of even date

For A A Mohare and Co.

Chartered Accountants (FRN 114152W)

For and on behalf of the Board of Directors of

Vaidya Sane Ayurved Laboratories Ltd

Amit Mohare

Partner

Membership No. 148601

Rohit Sane

MD & CEO

DIN: 00679851

Vidyt Ghag

Whole Time Director

DIN: 09299252

Abhishek Deshpande

Company Secretary

Darshan Shah

CFO

Place : Thane

Date : 27/05/2023

Place : Thane

Date : 27/05/2023

Place : Thane

Date : 27/05/2023

Place : Thane

Date : 27/05/2023

Place : Thane

Date : 27/05/2023

23148601B9WJJP6375



Particulars	Amounts in Lakhs	
	For the year ended	
	March 31, 2023	March 31, 2022
A. CASH FLOW FROM OPERATING ACTIVITIES :		
Net Profit before tax	691.04	474.89
Adjustments for:		
Depreciation and Amortization of Property, Plant and Equipment	259.79	228.57
Interest income	(87.27)	(14.69)
Dividend income	(0.05)	(0.05)
Rent income	(46.55)	(19.14)
Excess balance written off	(2.04)	-
Finance costs	18.75	20.18
Operating cash flows before Working Capital changes	833.67	689.76
Adjustments for Changes in Working Capital		
(Increase)/decrease in Inventory	(191.32)	11.43
(Increase)/decrease in Trade Receivables	(291.88)	(92.02)
(Increase)/decrease in Short term Loans and Advances	(335.02)	(1,795.36)
Increase/(decrease) in Trade Payables	161.45	63.08
Increase/(decrease) in Other Current Liabilities	32.27	(90.97)
Increase/(decrease) in Long - Term and Short - Term Provisions	10.16	1.74
CASH GENERATED FROM OPERATIONS	219.33	(1,212.34)
Taxes Paid	(262.26)	(119.14)
NET CASH FROM OPERATING ACTIVITIES	(42.93)	(1,331.48)
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase or construction of property, plant and equipment, Capital work in progress & Intangible assets	(697.91)	(317.20)
Proceeds from sale of tangible/intangible assets	-	18.36
Investment in quoted / unquoted shares	(105.36)	-
Proceeds from Fixed deposit	769.35	(487.13)
Rent Income	46.55	19.14
Dividend received	0.05	0.05
Interest Received	87.27	14.69
NET CASH USED IN INVESTING ACTIVITIES	99.95	(752.09)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from the issue of shares	-	277.12
Proceeds from the right issue of shares	-	76.73
Share premium	-	1,910.82
Increase / (Decrease) in Borrowings	(92.93)	4.69
Interim Dividend paid	(26.28)	-
Finance costs	(18.75)	(20.18)
NET CASH USED IN FINANCIAL ACTIVITIES	(137.96)	2,249.18
Net increase in Cash and Cash Equivalents	(80.94)	165.61
Cash and Cash Equivalents at beginning of the period	256.09	90.48
Cash and Cash Equivalents as end of the period	175.15	256.09

CASH AND CASH EQUIVALENTS:

Particulars	As at	As at
	March 31, 2023	March 31, 2022
On current accounts	157.21	77.30
Deposits with original maturity of less than 3 months	-	150.39
Cash on hand	17.94	28.40
	175.15	256.09

As per our report of even date

For A A Mohare and Co.

Chartered Accountants (FRN 114152W)

For and on behalf of the Board of Directors of

Vaidya Sane Ayurved Laboratories Ltd

Amit Mohare
Partner

Membership No. 148601

Place : Thane

Date : 27/05/2023

231486018GWJJP6375

Rohit Sane

MD & CEO

DIN: 00679851

Place : Thane

Date : 27/05/2023

Vidyt Ghag

Whole Time Director

DIN: 09299252

Place : Thane

Date : 27/05/2023

Abhishek Deshpande

Company Secretary

Place : Thane

Date : 27/05/2023

Darshan Shah

CFO

Place : Thane

Date : 27/05/2023





**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF CONSOLIDATED FINANCIAL RESULTS TO THE
BOARD OF DIRECTORS OF VAIDYA SANE AYURVED LABROTORIES LIMITED**

To,
The Board of Directors
Vaidya Sane Ayurved Laboratories Limited
(erstwhile known as Vaidya Sane Ayurved Laboratories Private Limited)
Fl. 5 1047, Shriram Bhawan,, Shukrawar Peth,
Pune, Maharashtra, India, 411002.

Dear Sir,

1. We have reviewed the accompanying Statement of Consolidated Audited Financial Results of **VAIDYA SANE AYURVED LABROTORIES LIMITED** (the "Company" or "Parent") and its subsidiary (the Parent and its subsidiary together referred to as the "Group"), and its share of the net profit after tax for the year ended March 31, 2023 (the "Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement of Consolidated financial information based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
4. The Statement includes the results of the following entity:


Sr. No.	Name of the Subsidiary	No. of Shares	Face Value	Value per Share paid	% holding in Company	Investment Value
1	Joint Healing Services Pvt Ltd	9900	10	10	99.00	99,000
2	F-health Accelerators Pvt Ltd	8000	10	10	80.00	80,000



5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with, does not give a true and fair view of the state of affairs of the Group as at March 31, 2023, and of its results of operations and its cash flows for the year ended in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed.
6. There are no uncertainties arising from the COVID 19 pandemic on which our conclusion on the Statement is modified in respect of this matter unless specifically mentioned.

For A A Mohare & Co.

Chartered Accountants (FRN : 114152W)


CA Amit A Mohare
Partner



Membership No. : 148601

Place : Thane

Date : 27/05/2023

UDIN : 23148601BGWJJO4191

Vaidya Sane Ayurved Laboratories Ltd

Fl No. 5, 1047, Shriram Bhavan, Shukrawar Peth, Pune, Maharashtra 411 002

CIN NO. : L73100PN1999PLC013509

Consolidated Statement of profit and loss for the Half year ended 31st March 2023 and year ended March 31,2023

Particulars	Amounts in Lakhs	
	For the Year Ended March 31,2023	For the Half year ended March 31,2023
Revenue		
Revenue from operations	9,916.89	5,358.17
Other income	136.09	53.58
Total revenue	10,052.98	5,411.75
Expenses		
Cost of materials consumed	2,762.24	1,455.79
Employee benefit expenses	2,199.93	1,116.13
Finance costs	18.75	7.45
Depreciation and amortisation expense	259.79	144.26
Other expenses	4,169.03	2,417.70
Total expenses	9,409.74	5,141.33
Profit / (loss) before prior period adjustments & tax.	643.24	270.42
Prior period adjustments		-
Profit / (loss) before extraordinary items and tax	643.24	270.42
Extraordinary items		-
Profit / (loss) before tax	643.24	270.42
Tax expense		
Current tax	172.26	72.96
Deferred tax (expense)/income	(12.26)	(12.18)
Profit for the year	483.24	209.64
Profit / (loss) Share of Minority Interest	(0.05)	(0.05)
Profit/(Loss) for the period from continuing operations	483.29	209.69
Earnings per equity share		
[Nominal value per share Rs. 10 (FY. 2021-22 - Rs.10)]		
Basic	4.60	1.99
Diluted	4.60	1.99

Notes :

- 1) The Audited Financial statement were reviewed by the audit committee and taken on record by the Board of directors at their meeting held on 27th May, 2023
- 2) As required under Regulation 33 of the SEBI (LODR) Regulations, 2015, the Statutory Auditors have issued Audit Report on the aforesaid audited financial results for the half year & year ended 31st March, 2023, which were also approved by the Audit Committee and board at their meeting held on Saturday, 27th May, 2023.
- 3) The Earning Per Share (EPS) has been computed in accordance with the Accounting Standard on Earnings Per Share (AS 20).
- 4) As per MCA Notification Wited 16th February, 2015, companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the compulsory requirement of adoption of IND-AS. As the company is covered under the exempted category, it has not adapted IND-AS for preparation of financial results.
- 5) The company has issued and allotted 27,71,200 equity share of face value INR 10/- each at a price of INR 73/- per share through an Initial Public Offer aggregating to INR 2022.98 lakhs. The net issue proceed after excluding Expenses is 1972.98 lakhs. The details of utilization of net IPO Proceeds is mentioned below,

Particulars	As per Prospectus	Actual Utilisation	Pending for Utilisation
Branding & Advertising	1,600	1452.78	147.22
General Corporate Purpose	372.98	372.98	0.00
Total	1972.98	1825.76	147.22

6) The losses applicable to the minority in a consolidated subsidiary may exceed the minority interest in the equity of the subsidiary. The excess, and any further losses applicable to the minority, are adjusted against the majority interest except to the extent that the minority has a binding obligation to, and is able to, make good the losses. If the subsidiary subsequently reports profits, all such profits are allocated to the majority interest until the minority's share of losses previously absorbed by the majority has been recovered.

7) Being a first year of consolidated financial statements comparative figures are not given.

For A A Mohare and Co.

Chartered Accountants (FRN 114152W)

Amit Mohare

Amit Mohare
 Partner
 Membership No. 148601
 Place : Thane
 Date : 27/05/2023
 UDIN : 23148601BQWJJC4191


For and on behalf of the Board of Directors of
Vaidya Sane Ayurved Laboratories Ltd

Rohit Sane

Rohit Sane
 MD & CEO
 DIN: 00679851

Vidut Ghag

Vidut Ghag
 Whole Time Director
 DIN: 09299252

Abhishek Deshpande

Abhishek Deshpande
 Company Secretary

Darshan Shah

Darshan Shah
 CFO

Date : 27/05/2023 Place : Thane
 Date : 27/05/2023 Place : Thane
 Date : 27/05/2023 Place : Thane
 Date : 27/05/2023 Place : Thane



		Amounts in Lakhs
Particulars		As at
		March 31, 2023
I	EQUITY AND LIABILITIES	
1. Shareholders' Funds		
Share Capital		1,051.35
Reserves and Surplus		2,993.92
		4,045.27
Minority interest		0.16
		4,045.43
2. Non-Current Liabilities		
Long-Term Borrowings		-
Deferred Tax Liabilities (Net)		-
Long-Term Provisions		155.32
		155.32
3. Current Liabilities		
Short-Term Borrowings		13.40
Trade Payables		-
(a) Total outstanding dues of micro enterprises and small enterprises		159.65
(b) Total outstanding dues of creditors other than micro enterprises and		736.84
Other Current Liabilities		329.61
Short-Term Provisions		48.13
		1,287.63
TOTAL		5,488.38
II	ASSETS	
1. Non-Current Assets		
Goodwill		-
Property, Plant & Equipment		-
Tangible assets		1,843.43
Intangible assets		251.34
Capital work in progress		167.21
Non-Current Investments		153.45
Deferred tax assets (net)		7.52
Long-Term Loans and Advances		286.99
		2,709.94
2. Current Assets		
Current Investment		1,379.51
Inventory		341.38
Trade receivables		599.04
Cash and Bank Balances		176.40
Short-Term loans and advances		282.11
Other Current Assets		-
		2,778.44
TOTAL		5,488.38

As per our report of even date

For A A Mohare and Co.
 Chartered Accountants (FRN 114152W)


 Amit Mohare
 Partner
 Membership No. 148601
 Place : Thane
 Date : 27/05/2023



For and on behalf of the Board of Directors of
 Vaidya Sane Ayurved Laboratories Ltd


 Rohit Sane
 MD & CEO
 DIN: 00679851
 Place : Thane
 Date : 27/05/2023


 Vidut Ghag
 Whole Time Director
 DIN: 09299252
 Place : Thane
 Date : 27/05/2023


 Abhishek Deshpande
 Company Secretary
 Place : Thane
 Date : 27/05/2023


 Darshan Shah
 CFO
 Place : Thane
 Date : 27/05/2023

231486018GWJT04191



Amounts in Lakhs

Particulars	For the year ended March 31, 2023
A. CASH FLOW FROM OPERATING ACTIVITIES :	
Net Profit before tax	643.24
Adjustments for:	
Depreciation and Amortization of Property, Plant and Equipment	259.79
Interest income	(87.27)
Dividend income	(0.05)
Minority interest	0.21
Rent income	(46.55)
Excess balance written off	(2.04)
Finance costs	18.75
Operating cash flows before Working Capital changes	786.08
Adjustments for Changes in Working Capital	
(Increase)/decrease in Inventories	(191.33)
(Increase)/decrease in Trade Receivables	(244.44)
(Increase)/decrease in Loans and Advances	(285.99)
Increase/(decrease) in Trade Payables	161.98
Increase/(decrease) in Other Current Liabilities	32.21
Increase/(decrease) in Provisions	10.16
CASH GENERATED FROM OPERATIONS	268.67
Taxes Paid	(262.26)
NET CASH FROM OPERATING ACTIVITIES	6.41
B. CASH FLOW FROM INVESTING ACTIVITIES	
Purchase or construction of property, plant and equipment, Capital work in progress & Intangible assets	(697.91)
Investment in shares	(153.44)
Proceeds from Fixed deposit	769.34
Dividend income	0.05
Rent Income	46.55
Interest Received	87.27
NET CASH USED IN INVESTING ACTIVITIES	51.86
C. CASH FLOW FROM FINANCING ACTIVITIES	
Proceeds from the issue of shares	
Share premium	
(Repayment) of Borrowings	
Proceeds from Borrowings	(92.93)
Interim dividend paid	(26.28)
Finance costs	(18.75)
NET CASH USED IN FINANCIAL ACTIVITIES	(137.96)
Net increase in Cash and Cash Equivalents	(79.69)
Cash and Cash Equivalents at beginning of the period	256.09
Cash and Cash Equivalents received on acquisition	
Exchange loss/ (gain) on translation of foreign currency cash	
Cash and Cash Equivalents as end of the period	176.40






CASH AND CASH EQUIVALENTS:

Particulars	As at March 31, 2023
On current accounts	158.46
Deposits with original maturity of less than 3 months	-
Cash on hand	17.94
	176.40

As per our report of even date

For A A Mohare and Co.
 Chartered Accountants (FRN 114152W)

For and on behalf of the Board of Directors of
 Vaidya Sane Ayurved Laboratories Ltd

 Amit Mohare Partner Membership No. 148601 Place : Thane Date : 27/05/2023	 Rohit Sane MD & CEO DIN: 00679851 Place : Thane Date : 27/05/2023	 Vidyut Ghag Whole Time Director DIN: 09299252 Place : Thane Date : 27/05/2023	 Abhishek Deshpande Company Secretary Place : Thane Date : 27/05/2023	 Darshan Shah CFO Place : Thane Date : 27/05/2023
--	--	--	---	--

2314860186WJJ04191



Particulars	Hospital Activity				Sale of Product Activity				Common/ Unallocable				Total			
	Half Year Ended March 31, 2023	Half Year Ended March 31, 2022	Year Ended March 31, 2023	Year Ended March 31, 2022	Half Year Ended March 31, 2023	Half Year Ended March 31, 2022	Year Ended March 31, 2023	Year Ended March 31, 2022	Half Year Ended March 31, 2023	Half Year Ended March 31, 2022	Year Ended March 31, 2023	Year Ended March 31, 2022	Half Year Ended March 31, 2023	Half Year Ended March 31, 2022	Year Ended March 31, 2023	Year Ended March 31, 2022
REVENUE																
Segment Revenue	1,069.85	865.05	1,987.70	1,542.03	3,194.18	2,557.73	5,979.19	4,463.94	1,085.79	863.99	1,935.65	1,437.20	5,349.82	4,286.76	9,902.54	7,443.17
RESULT																
Other Segment Revenue	-	-	-	-	-	-	-	-	53.59	33.84	136.10	33.94	53.59	33.84	136.10	33.94
Material Consumed (Including direct	219.94	115.73	412.98	246.00	1,305.57	1,054.84	2,418.98	1,863.96	-	13.19	-	17.93	1,525.51	1,183.76	2,831.97	2,127.88
Corporate Expenses	509.90	477.16	934.11	824.28	-	-	-	-	2,925.56	2,197.10	5,302.97	3,801.30	3,435.46	2,674.25	6,237.08	4,625.58
Operating Profit	340.01	272.16	640.60	471.75	1,888.61	1,502.89	3,560.21	2,599.98	(1,786.17)	(1,312.45)	(3,231.21)	(2,348.09)	442.44	462.59	969.60	723.64
Interest Cost	-	-	-	-	-	-	-	-	7.45	9.30	18.74	20.18	7.45	9.30	18.74	20.18
Depreciation	16.27	20.23	28.85	20.23	-	-	-	-	128.02	90.89	230.97	208.34	144.29	111.12	259.82	228.57
Income Taxes	-	-	-	-	-	-	-	-	72.96	101.89	172.26	119.14	72.96	101.89	172.26	119.14
Deferred Tax Provision	-	-	-	-	-	-	-	-	(0.14)	28.86	(0.22)	8.85	(0.14)	28.86	(0.22)	8.85
Net profit	323.74	251.93	611.75	451.52	1,888.61	1,502.89	3,560.21	2,599.98	(1,994.46)	(1,543.39)	(3,652.97)	(2,704.61)	217.89	211.43	519.00	346.89
OTHER INFORMATION																
Segment Assets	1,337.01	1,076.62	1,337.01	1,076.62					4,190.87	3,923.97	4,190.87	3,923.97	1,337.01	1,076.62	1,337.01	1,076.62
Unallocable Corporate Assets													4,190.87	3,923.97	4,190.87	3,923.97
Total Assets	1,337.01	1,076.62	1,337.01	1,076.62					4,190.87	3,923.97	4,190.87	3,923.97	5,527.88	5,000.59	5,527.88	5,000.59
Segment Liabilities	123.86	137.89	123.86	137.89					-	-	-	-	123.86	137.89	123.86	137.89
Unallocable Corporate Liabilities									5,404.02	4,862.70	5,404.02	4,862.70	5,404.02	4,862.70	5,404.02	4,862.70
Total Liabilities	123.86	137.89	123.86	137.89					5,404.02	4,862.70	5,404.02	4,862.70	5,527.88	5,000.59	5,527.88	5,000.59
Capital Expenditure																
Depreciation									566.13	216.92	765.46	293.53	566.13	216.92	765.46	293.53
Non Cash Expenditure other than Depreciation									128.02	90.89	230.97	208.34	128.02	90.89	230.97	208.34
									4.48	(25.68)	(4.26)	(34.77)	4.48	(25.68)	(4.26)	(34.77)







Date: 27th May 2023

To,
Listing Compliance Department,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra East, Mumbai-400051


NSE Symbol: Madhavbaug

Sub: Declaration of Unmodified Audit report

Pursuant to requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, as amended from time to time and other applicable provisions, if any, it is hereby informed that statutory auditors have given unmodified opinion for Audited Financial Results for year ended March 31, 2023.

We would request you to take the above intimation on records.

For, Vaidya Sane Ayurved Laboratories Limited



Abhishek Deshpande

Company Secretary & Compliance officer



VAIDYA SANE AYURVED LABORATORIES LIMITED

Registered Office Address:

Fl.5 1047, Shriram Bhawan, Shukrawar Peth,
Pune- 411002, Maharashtra India.
CIN No : L73100PN1999PLC013509

Corporate Office Address:

Ishan Bldg. No. 2, 701, 7th Floor, Gokhale Road, Naupada,
Thane (W)-400 602. Tel: +91 022-41235315/16
www.madhavbaug.org

ANNEXURE-2

Brief details of Appointment of M/s Khare Deshmukh & Co, Chartered Accountant, Pune as Internal Auditor of the Company for FY 2023-24

We further submit following details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No: CIR/CFD/CMD/4/2015 dated 09th September 2015.

Particulars	Description
Name of Statutory Auditor	M/s Khare Deshmukh & Co, Chartered Accountants, Pune (Firm Registration No: 116141W)
Reason for change Viz., Appointment, Resignation, Removal, Death or otherwise;	Appointment
Date of Appointment/ cessation & term of Appointment	27 th May 2023 (Term of Appointment: FY 2023-24)
Brief Profile (In case of Appointment)	M/s Khare Deshmukh & Co, Chartered Accountants, Pune, is a partnership Firm having 20+ years of industry experience and seasoned accounting professionals in the team speak of our unmatched expertise in the field of accounting.
Disclosure of Relationship between Directors (in case of appointment of Director)	Not applicable



VAIDYA SANE AYURVED LABORATORIES LIMITED

Registered Office Address:
 Fl.5 1047, Shriram Bhawan, Shukrawar Peth,
 Pune- 411002, Maharashtra India.
 CIN No : L73100PN1999PLC013509

Corporate Office Address:
 Ishan Bldg. No. 2, 701, 7th Floor, Gokhale Road, Naupada,
 Thane (W)-400 602. Tel: +91 022-41235315/16
www.madhavbaug.org

ANNEXURE-3

Brief details of Appointment of M/s Deep Shukla & Associates, Practising Company Secretaries, Mumbai as Secretarial Auditor of the Company for FY 2023-24

We further submit following details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No: CIR/CFD/CMD/4/2015 dated 09th September 2015.

Particulars	Description
Name of Statutory Auditor	M/s Deep Shukla & Associates (Membership No: 5652 & Certificate of Practice Number: 5364)
Reason for change Viz., Appointment, Resignation, Removal, Death or otherwise;	Appointment
Date of Appointment/ cessation & term of Appointment	27 th May 2023 (Term of Appointment: FY 2023-24)
Brief Profile	M/s Deep Shukla & Associates is sole proprietorship firm providing Secretarial consultancy and Advisory Services since 2003. They cater wide range of services to our clients with the purpose of turning our expertise into value for the benefit of our clients.
Disclosure of Relationship between Directors (in case of appointment of Director)	Not applicable



VAIDYA SANE AYURVED LABORATORIES LIMITED

Registered Office Address:

Fl.5 1047, Shriram Bhawan, Shukrawar Peth,
Pune- 411002, Maharashtra India.
CIN No : L73100PN1999PLC013509

Corporate Office Address:

Ishan Bldg. No. 2, 701, 7th Floor, Gokhale Road, Naupada,
Thane (W)-400 602. Tel: +91 022-41235315/16
www.madhavbaug.org